Neprilysin (NEP), also known as neutral endopeptidase, enkephalinase, CD 10, and common acute lymphoblastic leukemia antigen, is a 97-kD protein. NEP can degrade amyloid ß peptides, and its mRNA and protein levels are known to be reduced in the brains of patients with Alzheimer's disease (AD), making the NEP gene a substantial candidate for an AD risk factor. We examined the genetic association of three NEP polymorphisms, a GTrepeat polymorphism and two single nucleotide polymorphisms (SNPs, -1075A1G and -1284G1C) in its promoter region, with AD in a Japanese case-control sample (240 patients and 163 controls). The GT-repeat polymorphism, but not the SNPs, was significantly associated with late-onset AD (p = 0.0007). Our findings suggest that the GT-repeat polymorphism in the promoter region of the NEP gene or some other unknown polymorphisms, which are in a linkage disequilibrium, confer a susceptibility to late-onset AD.
Introduction
Alzheimer's disease (AD) is a common disease, and susceptibility to AD is thought to be regulated by multiple genetic and environmental factors. Pathologically, AD is characterized by deposits of amyloid plaques, neurofibrillary tangles, and neuron death in the brain. The major constituents of the amyloid plaques are amyloid ß peptides (Aß), composed of 40-42 amino acids, which are derived from ß-and subsequent Á-secretase cleavage of the ß-amyloid precursor protein [1] . Abundant evidence suggests that the accumulation of extracellular Aß contributes significantly to the pathology of AD. Therefore, therapeutic approaches for reducing amyloid deposition, including the use of proteolytic enzymes to break down Aß and inhibitors of ß-and Á-secretases, might be useful for slowing the progression of AD.
Neprilysin (NEP, MIM No. 120520), also known as neutral endopeptidase (EC 3.4.24.11, membrane metalloendopeptidase, enkephalinase, CD 10, and common acute lymphoblastic leukemia antigen), is a 97-kD protein that is widely expressed in many tissues, including the brain. The NEP gene is located on chromosome 3q 25.1-q25.2. Recently, NEP has been proposed as a candidate protease that degrades Aß in the brain [2] [3] [4] [5] [6] . The infusion of a NEP inhibitor into the rat brain resulted in the pathological deposition of endogenous Aß [2] . The mRNA and protein levels of NEP in the hippocampus and middle temporal gyrus of AD patients were also significantly lower than those of controls [6] . These results suggest that a down-regulation in NEP transcription and activity might raise the risk of developing AD by enhancing the accumulation of Aß. Several polymorphisms in the promoter region of the NEP gene have been identified, including a GT-repeat polymorphism [7, 8] and two single nucleotide polymorphisms [SNPs, -1075A1G (IMS-JST129280) and -1284G1C (IMS-JST129281)] [9] . Polymorphisms in the promoter region can affect the expression of the gene's mRNA. Here, we investigated the genetic association of these NEP gene polymorphisms in the promoter region with AD in a Japanese population using a casecontrol study.
Materials and Methods
The subjects were 240 patients with AD (67 males and 173 females; mean age, 74.4 years; SD 9.6), who met the NINCDS-ADR-DA and DSM-IV criteria for AD, and 163 controls (45 males and 118 females; mean age, 72.9 years; SD 7.6). Eighty-four patients (33 males and 51 females; mean age, 65.0 years; SD 8.1) suffered from early-onset (! 65 years old) AD (EOAD) and 156 patients (34 males and 122 females; mean age, 79.4 years; SD 5.9) suffered from late onset (665 years old) AD (LOAD). All the subjects were Japanese, born and living in the mid-west area of Japan.
This study was performed after approval by the ethics committee of Okayama University Graduate School of Medicine and Dentistry. All blood samples for genotyping were obtained in accordance with the written informed consent procedures approved by the committee.
Genomic DNA was extracted from peripheral leukocytes using the standard phenol/CHCl 3 method. Each region containing polymorphisms was amplified by polymerase chain reaction (PCR) using the following primer sets: for the GT-repeat polymorphism, 5)-GCAGTAAATCATTTTGATATTAAA-3) (forward primer) and 5)-TGATCCTTTCCTCTTTTGAAT-3) (reverse primer); for the -1075A1G polymorphism, 5)-AATTCATACTGAAATAAAAC-TGGGTTCGC-3) (forward primer, underline shows the mismatched nucleotide used to create a Bsh1236I cognitive site for the -1075 G allele) and 5)-GCTTTTCAGCTTTCTCTGNCTATG-3) (reverse primer); for the -1284G1C polymorphism, 5)-CTGG-GTTTGCRATTATCTGTTTTTA-3) (forward primer) and 5)-GG-ATTGTTGTGAGGACTAAATAGTG-3) (reverse primer). PCR was performed in a final volume of 15 Ìl using 10% dimethyl sulfoxide and 1 unit of Extaq (TaKaRa Co., Japan) in the reaction mixture. PCR conditions were as follows: GT-repeat polymorphism, 95°C for 5 min followed by 35 cycles of 95°C for 30 s, 55°C for 1 min and 72°C for 1 min, with a final extension of 5 min at 72°C in the last cycle; -1075A1G and -1284G1C polymorphisms, 95°C for 5 min followed by 35 cycles of 95°C for 30 s, 54°C for 30 s and 72°C for 30 s, with a final extension of 5 min at 72°C in the last cycle. To analyze the polymorphic GT-repeat, the reverse primer was labeled with Texas Red, and the PCR products and a Texas Red-labeled size standard were electrophoretically run on a 6% polyacrylamide gel using an SQ5500 DNA sequencer (Hitachi Co., Japan); each length was calculated using Fragyls 2 (Hitachi Co.) computer software. The -1075A1G and -1284G1C polymorphisms were analyzed on 3.5% agarose gels after digestion with Bsh1236I and HinfI, respectively. The apolipoprotein E genotypes were analyzed according to the method described by Wenham et al. [10] .
All genotyping was carried out in a blinded fashion, with the control and case samples mixed randomly. Allele frequencies were calculated using the allele-counting method. The statistical significance of all associations was assessed using standard contingency table analyses, the ¯2 and Fisher's exact test. For the GT-repeat polymorphism, p values were empirically obtained using Monte Carlo simulations, as implemented in the CLUMP program [11] . CLUMP is useful for case-control comparisons of multiallelic genetic markers. Logistic regression analysis was used to estimate the odd ratio (OR) between the GT-repeat polymorphism genotype and developing AD. Additionally, to determine a possible effect of the GT-repeat polymorphism on age of onset, an unpaired t-test was carried out for AD patients. The pairwise linkage disequilibrium was calculated using the ¯2 test, based on the differences between the observed and expected numbers of haplotypes. Haplotype frequencies were estimated using the EH program [12] .
Results
For the three polymorphisms analyzed, the data obtained for the patients and controls was in Hardy-Weinberg equilibrium (two SNPs: controls, ¯2 = 0, p = 1.0; patients, ¯2 = 0, p = 1.0; GT-repeat polymorphism: controls, ¯2 = 12.2, p = 0.28; patients, ¯2 = 7.4, p = 0.76).
The allelic distributions of the GT-repeat polymorphism in the promoter region in patients and controls are shown in table 1. The number of GT-repeats ranged from 18 to 25, among which a 24-repeat allele was not observed. The overall allelic distribution differed significantly in the all AD patient group and the LOAD group from the controls (all AD, ¯2 = 13.14, p = 0.0021; LOAD, 2 = 15.67, p = 0.0007; statistical p values obtained using the CLUMP program). An analysis of the frequency of each GT-repeat polymorphism compared to the other polymorphisms indicated that the 19-repeat and 22-repeat alleles were overrepresented in the all AD and LOAD groups. Among them, the 22-repeat allele of the GT-repeat polymorphism in the LOAD group was significantly different from that in the controls, even after using Bonferroni's correction (¯2 = 8.82, d.f. = 1, p = 0.0028; critical p value for 6 alleles is 0.0083; statistical p values were calculated using Fisher's exact test). As expected, the APOE-Â4 allele was significantly associated with AD (p ! 0.0001, data not shown). The control and AD patient groups were divided into two subgroups according to their APOE status: E4+ and E4-(table 2). E4+ indicates the presence of one or two Â4 alleles of APOE, while E4-indicates the absence of the Â4 allele. The distribution of GTrepeat polymorphisms was significantly different between the E4-subgroup of EOAD and the E4-subgroup of the controls (p = 0.0131). However, this difference did not remain significant after Bonferroni's correction was applied. We next performed the logistic regression analysis. ; p = 0.035), respectively. This result revealed the interaction between the 22-repeat allele and APOE-Â4 allele on risk for LOAD. Additionally, we performed an unpaired t-test on AD patients with age at onset as the dependent variable and GT-repeat polymorphism as the independent variable. There was no significant effect of the 22-repeat allele on age at onset of this disease (t = 1.099, p = 0.272). The distributions of the -1075A1G and -1284G1C polymorphisms in the patients and controls are shown in table 3. No significant differences between the distributions of these polymorphisms were observed when the all AD and control groups, the EOAD and control groups, and the LOAD and control groups were compared. Furthermore, the differences were not significant even when the distributions of these SNPs were divided into subgroups according to APOE status (data not shown).
Using the maximum-likelihood method, the pairwise linkage disequilibrium between the two SNPs and the GT-repeat polymorphism was separately estimated for the all AD and control groups. The p values for pairwise linkage disequilibrium are shown in table 4 (with regard to the subtypes of AD, data not shown). Linkage disequilibrium was observed between the -1075A1G polymorphism and the GT-repeat polymorphism in control, all AD, and EOAD groups. We estimated the two-site haplotype frequencies (the -1075A1G polymorphism and the GT-repeat polymorphism) between cases and controls using the EH program. No significant differences in haplotype frequencies were observed between the all AD and the control groups or between the EOAD and the control groups (d.f. = 13, all AD and controls: ¯2 = 18.80, p = 0.129; EOAD and controls: ¯2 = 10.12, p = 0.684).
Discussion
The present study demonstrated a significant association between LOAD and the GT-repeat polymorphism in the promoter region of the NEP gene; furthermore, the 22-repeat allele of this polymorphism was significantly more common in the LOAD group than in the control group. Two explanations are possible for the influence of the 22-repeat allele on NEP activity. First, the polymorphism itself may have a functional effect on the NEP transcription rate. Alternatively, this allele of the GT-repeat polymorphism may be in linkage disequilibrium with another polymorphism, either within or outside of the NEP gene, that modifies NEP activity or function; a certain haplotype associated with the 22-repeat allele of the GT-repeat polymorphism may confer a susceptibility to the development of AD. Previous studies have indicated that the GT-repeat polymorphism of the NEP gene must functionally affect some phenotypes. Comings et al. [7, 8] showed that the genotype of the NEP gene was significantly associated with phobic anxiety, obsessive-compulsive and anxiety symptoms, and a low P300 amplitude, a cognitive event-related brain potential in male patients with substance abuse. These studies indicate that the GTrepeat polymorphism of the NEP gene may affect neuropsychiatric functions in the central nerve system.
Two previous studies reported a negative association between NEP gene polymorphisms and AD. Oda et al. [13] examined four kinds of dinucleotide repeat polymorphisms of the NEP gene and found a tendency, but not a significant association, between AD and two polymorphisms (AC and GT-repeat polymorphisms) located upstream of exon 1. Their results seem to be inconsistent with ours. The present study showed that the NEP gene was associated with LOAD but not with EOAD. Oda et al. [13] stated that neither EOAD nor LOAD were associated with the polymorphisms. However, they did not provide detailed data (e.g., the ratio of EOAD and LOAD). The average age of AD patients examined in their study was about 4 years younger than in ours. Therefore, EOAD may have been predominant among the AD subjects in their study, possibly resulting in the inconsistency between their results and ours.
Sodeyama et al. [14] examined the association of the GT-repeat polymorphism of the NEP gene with AD and AD-type neuropathological changes. They found no association with the disease and also showed no association between the gene polymorphism and densities of senile plaques, senile plaques with dystrophic neurites, and neurofibrillary tangles in the hippocampus or superior temporal gyrus. However, their sample size was considerably smaller than ours because it was a postmortem study. Furthermore, they did not classify their subjects into EOAD and LOAD subgroups. These factors may have resulted in the inconsistency between their findings and ours.
Although there was no significant difference in the distribution of GT-repeat polymorphisms of the NEP gene when subdivided according to the APOE status (E4+ group and E4-group), the logistic regression analysis revealed the interaction between the 22-repeat allele and APOE-Â4 allele on risk for LOAD.
In the present study, we identified a significant association between the NEP gene and a susceptibility to LOAD. To confirm our findings, this analysis should be repeated in independent cohorts of AD patients, especially cohorts of other ethnic populations. When the all AD group was classified into EOAD and LOAD subgroups, with regard to EOAD, the statistical power to detect a small size (w = 0.12) declined below 0.8 (all AD: 0.924; LOAD: 0.854; EOAD: 0.755). In addition, the average age of EOAD patients was about 8 years younger than that of controls. This might explain the lack of association observed in the EOAD group. Therefore, our results must be qualified after the recruitment of additional EOAD patients and controls. As we examined only the polymorphisms in the promoter region of the NEP gene, other polymorphisms in the exons and 3) flanking region of the gene must also be examined, and additional haplotype analyses may reduce the possibility of false results. More data on the relationship between the GT-repeat polymorphisms and NEP function will be necessary to obtain a complete understanding of the precise mechanism by which the NEP gene confers an increased susceptibility to the development of LOAD.
